Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.
The investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.
精彩评论